A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

PURPOSE: Combining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors (Ki67 > 15%). METHODS: This randomized, multi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Baselga, José, Morales, Serafin M., Awada, Ahmad, Blum, Joanne L., Tan, Antoinette R., Ewertz, Marianne, Cortes, Javier, Moy, Beverly, Ruddy, Kathryn J., Haddad, Tufia, Ciruelos, Eva M., Vuylsteke, Peter, Ebbinghaus, Scot, Im, Ellie, Eaton, Lamar, Pathiraja, Kumudu, Gause, Christine, Mauro, David, Jones, Mary Beth, Rugo, Hope S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448790/
https://ncbi.nlm.nih.gov/pubmed/28324268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4199-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados